Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

Journal of the National Cancer Institute

Volumn 100, Issue 4, 2008, Pages 261-269

  Fakhry, Carole ^a   Westra, William H ^a   Li, Sigui ^b   Cmelak, Anthony ^c   Ridge, John A ^e   Pinto, Harlan ^d   Forastiere, Arlene ^a   Gillison, Maura L ^a,f  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d STANFORD UNIVERSITY   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GENOMIC DNA; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; COVARIANCE; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HAZARD RATIO; HEAD AND NECK CARCINOMA; HEALTH STATUS; HUMAN; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLEX POLYMERASE CHAIN REACTION; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CANCER; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS LOAD; WART VIRUS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANALYSIS OF VARIANCE; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; HEAD AND NECK TUMOR; HUMAN PAPILLOMAVIRUS TYPE 16; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RADIATION DOSE FRACTIONATION; REMISSION; RISK; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IN SITU HYBRIDIZATION; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PACLITAXEL; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 39649109915     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn011     Document Type: Article

References (22)

1. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31(6):744-754.
2. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-720.
4. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg. 2001;125(1)1-9.
5. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736-747.
6. Cmelak A, Li S, Goldwasser M, et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol. 2007;25(25):3971-3977.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
8. Wain SL, Kier R, Vollmer RT, Bossen EH. Basaloid-squamous carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. Hum Pathol. 1986;17(11):1158-1166.
9. Huang CC, Qiu JT, Kashima ML, Kurman RJ, Wu TC. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol. 1998;11(10):971-977.
10. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2003;9(17):6469-6475.
11. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361.
12. Gravitt PE, Peyton C, Wheeler C, Apple R, Higuchi R, Shah KV. Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods. 2003;112(1-2):23-33.
13. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods. 2001;91(2):109-117.
14. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003;162(3):747-753.
15. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res. 2005;11(16):5694-5699.
16. O'Neill CJ. McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol. 2006;13(1):8-15.
17. Dai M, Clifford GM, le Calvez F, et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res. 2004;64(2):468-471.
18. Mellin Dahlstrand H, Lindquist D, Bjornestal L, et al. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res. 2005;25(6C):4375-4383.
19. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92(4):805-813.
20. Ferris RL, Martinez I, Sirianni N, et al. Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer. 2005;41(5):807-815.
21. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24(36):5630-5636.
22. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95(23):1772-1783.